Promotional material

Vaccine update: issue 350, September 2024

Published 8 October 2024

Applies to England

Stay protected this autumn

Following advice from the Joint Committee on Vaccination and Immunisation (JCVI), the government has approved an autumn COVID-19 vaccination programme this year. Individuals who are 65 years or older, or live in a care home for older people, or are aged 6 months or over who are in a clinical risk group, are all eligible to get their autumn vaccine against COVID-19.

COVID-19 vaccination will begin in early October, coinciding with the main flu vaccination campaign. As the JCVI advises, this will provide optimal protection during the highest risk period when the flu is likely to circulate.

Data from last year’s autumn programme shows that vaccine uptake for those aged 65 and over was approximately 70%. Vaccination continues to offer the best protection for those at risk of serious outcomes, due to older age or clinical condition. By getting a dose of the COVID-19 vaccine this autumn, you can top up your protection against serious disease, as immunity from previous vaccines will wane over time.

Dr Mary Ramsay, Director of Public Health Programmes at UKHSA, said:

Our ongoing surveillance shows that COVID-19 continues to cause severe illness, putting many in hospital, particularly older people and those with underlying medical conditions. But it also shows that the autumn vaccines are effective in helping to give added protection to those most at risk.

Last year’s data also shows that those who received a vaccine were around 45% less likely to be admitted to hospital with COVID-19, compared to those who did not receive one.

We have produced a variety of resources, which are available on the Health Publications website, in multiple translations and accessible versions, to help promote vaccine to those eligible and for outreach and uptake in underserved and under-vaccinated communities.

It is important that those who are eligible get vaccinated as soon as possible once invited, ahead of any winter outbreaks of COVID-19 and flu, so that they are protected against serious illness and hospitalisation.

We would like to extend our thanks to all for their hard work delivering the programme.

JCVI advice on autumn vaccination programme

The JCVI published a statement on 2 August 2024 regarding the COVID-19 vaccination programme for autumn 2024. As the country has transitioned from pandemic response to recovery, the JCVI has continued to adapt their advice accordingly. Each dose of the COVID-19 vaccine increases protection against hospitalisation by 50% to 60%, but protection wanes over the following 3 to 6 months. That is why for those who are most vulnerable, it is necessary to offer a booster dose.

For this autumn, the JCVI has advised that the following cohorts should be offered a COVID-19 vaccine, usually no earlier than around 3 months after the last vaccine dose:

• adults aged 65 years and over
• residents in a care home for older adults
• persons aged 6 months to 64 years in a clinical risk group (see tables 3 and 4 of chapter 14a of the Green Book for more details)

The focus of the autumn programme is to offer vaccination to those most likely to directly benefit, in particular those with underlying health conditions that increase their risk of hospitalisation following infection.

COVID-19: the Green Book

COVID-19, the Green Book chapter 14a has been updated to include vaccine choice, doses and eligibility criteria for the autumn 2024 vaccination programme. It also includes most recent vaccine effectiveness data, case and variant epidemiology and updated safety information.

COVID-19 vaccination programme e-learning now available

The e-learning provides information about the national COVID-19 vaccination programme, which began in the UK in December 2020 to protect against serious illness and death from the SARS-CoV-2 virus. It is designed for healthcare practitioners who are involved in the delivery of the COVID-19 vaccination programme. It includes information on how to safely and effectively deliver the programme and promote high uptake of the vaccine.

New online service for infectious disease notifications

Notifying cases of infectious disease has become easier thanks to a new online service launched by UKHSA. Registered Medical Practitioners have a legal duty to notify any suspected or confirmed cases of any diseases included on the notifiable list. This information goes to UKHSA to make sure that the correct public health action is taken quickly to protect patients, their families, and the wider community.

Until now, notification has been through a paper, telephone, and email-based system. However, on Thursday 12 September, UKHSA launched ‘Report a Notifiable Disease’ – a new online service which will mean notifications can be made quickly and easily via gov.uk.

On this new page, doctors or clinicians will be able to access a simple form which will take them quickly and easily through all the information which needs to be entered for a case, and this will be sent directly to UKHSA.

Urgent cases will still need to be telephoned through to UKHSA, particularly out of hours to ensure a prompt response. A paper form is also available to download on the gov.uk page for any colleagues who are unable to access the new online service. Further information about the process and training videos can be found on the webpage.

Childhood immunisations campaign: latest data available

The annual childhood vaccination coverage statistics were published on 17 September. This statistical report is co-authored by UKHSA and NHS England and covers data from 1 April 2023 to 31 March 2024. The page includes an interactive coverage dashboard providing local authority-, region- and England-level data.

The accompanying press release from NHS England highlights the latest measles, mumps and rubella (MMR) data and how vaccines are our best form of protection against serious illness. According to the data, nearly 1 in 6 children had not received both doses of the MMR vaccine by the age of 5.

Dr Vanessa Saliba, Consultant Epidemiologist at UKHSA, said:

Our drive to increase vaccine uptake must continue so that no child is left at risk of serious illness or life-long complications.

These vaccines offer the best protection as children start their journey into nursery and mixing more widely.

Many who missed out on their vaccinations have already been caught up, but more needs to be done to ensure all those eligible are vaccinated.

The second wave of the Childhood Immunisation Marketing Campaign is live across England, with campaign activity running until 4 October 2024, as part of our drive to increase vaccine uptake.

The campaign, delivered by UKHSA in partnership with the Department for Health and Social Care and NHS England, will remind parents and carers of the risk to their children missing out on protection against serious diseases, including measles, whooping cough, meningitis, diphtheria and polio.

It’s aimed at all parents and carers/guardians of children aged 0 to 4 whose child has missed, or will miss, a childhood vaccination by age 5, and we need support from everyone to help us communicate the importance of parents getting their children vaccinated.

You can help us by:

• sharing information about the campaign with your networks – we have a wide variety of resources to share with your audiences including posters, postcards, social media and digital screen graphics, skyscraper banners, videos, suggested copy and translated materials
• helping us find case studies – we are looking for case studies of children hospitalised as a result of not being vaccinated, whose parent(s), carer(s) or guardian(s) is (are) willing to share their experiences in the press or on social media to encourage others to take up the vaccine offer
• getting in touch if you’re holding an event – if you are planning a webinar, briefing or other event please get in touch with externalaffairs@ukhsa.gov.uk so we can see how best to support you

An updated communications toolkit is available with more information about how to promote the campaign, and this can also be found on the Childhood Immunisations section of the Campaign Resource Centre. Printed materials can be ordered from the Health Publications website.

Publications

A guide to the COVID-19 autumn vaccination

This leaflet contains updated information on the autumn 2024 vaccination programme for COVID-19. It explains who is being offered COVID-19 vaccination this autumn, the timing of vaccination and which vaccine will be offered. The English version of the leaflet is available to order or download for free using product code C24AEN. Translations and accessible versions will be available in due course.

Which COVID-19 vaccine?

This poster contains information on the presentation, doses and storage of COVID-19 vaccines. It is suitable for use in all healthcare and vaccination settings, and is free to order using product code 24COV01WVP.

Stickers

Have you ordered your stickers?

The use of stickers is helpful to promote peer-to-peer signalling that the eligible person or child has had their vaccine. They can be a useful distraction whilst you prepare vaccines for administration, discuss with parents and even for adults to select the sticker that they want. We have a range of stickers for various programmes. Place your order today.

‘I’ve had my vaccines’ sticker

These stickers are available in two designs, butterfly and bear. The stickers are available in sheets of 24 and can be ordered using product codes IMMBTFL1 and IMMBEAR1.

Flu vaccine sticker

These stickers are for healthcare practitioners to give to children aged 2 to 11 who have received a flu vaccine either at their GP practice or at primary school. The stickers are available in sheets of 72 and can be ordered using product code SCHFLSTK.

Autumn COVID-19 booster sticker

These stickers are for healthcare practitioners to give to individuals who have received their autumn COVID-19 booster vaccine. They are available in sheets of 55 and can be ordered using product code COVIDAUT22.

‘I’ve had my COVID vaccination’ sticker

These stickers are for healthcare practitioners to give to individuals who have received a COVID-19 vaccine. They are available in sheets of 50 and can be ordered using product code COV2020350.

‘I’ve had my shingles vaccine’ sticker

These stickers are for anyone eligible for a shingles vaccine. They are available in sheets of 24 and can be ordered using product code S23ST04.

Feedback from school-age immunisers

Here at the School-aged Immunisation Team across Rotherham, Derbyshire and Nottinghamshire, we have introduced the use of butterfly and bear stickers to hand out to the children following their immunisation of HPV, Dtap, MenACWY and MMR throughout January to August.

Our teams found that school years 8 and 9 accepted the stickers and really liked them. Older pupils in years 10 and 11, who were attending catch-up vaccination sessions following call and recall for missed vaccinations, leaned more towards declining the stickers as they felt they were too old for one. However, this did not affect uptake of vaccinations within this cohort.

The stickers were helpful as an incentive to get vaccinated. Our punchline to the pupils was ‘Wear your sticker with pride and be a real life superhero’.

The younger cohorts are more likely to be afraid of vaccination due to fears of it hurting, but the stickers worked well with encouraging them to have their vaccinations and protect themselves.

In addition to this, we found that pupils in SEND schools really liked the stickers as they were shiny and colourful. SEND schools tend to have extremely low vaccination uptake, therefore, using the stickers proved effective in increasing uptake.

Since trialling the stickers in January, we have decided to continue to use them for SEND children and years 8 to 11 throughout the year for adolescent vaccinations, and use the flu stickers from September. We believe the quality of the stickers also contributes to pupils having a positive experience when receiving their vaccinations.

Pete Rudkin, Immunisations Team Leader

Vaccine supply

Routine vaccination programme

Change of vaccine brand for meningococcal groups A, C, W and Y (MenACWY) vaccination

The vaccine used for meningococcal groups A, C, W and Y (MenACWY) vaccination will change from Nimenrix® to MenQuadfi®. The change is expected to happen during October 2024. Please continue to order and administer Nimenrix® until ImmForm and local stockholdings deplete.

When MenQuadfi® vaccine is made available to order via ImmForm, high-level ordering controls will be in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

MenQuadfi® vaccine ordered via ImmForm will be supplied as a single-dose pack, containing one vial of vaccine and a Patient Information Leaflet (PIL). The pack does not contain a needle or a syringe for administration. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. Needles and syringes should be obtained locally.

MenQuadfi® and Nimenrix® vaccines are packed in different sized cartons. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, the dimensions are as follows:

• MenQuadfi® is 58 x 32 x 45mm (H x W x D)
• Nimenrix® was 57 x 27 x 135mm (H x W x D)

Please add MenQuadfi® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

Details about the meningococcal vaccination programme is published in chapter 22 of the Green Book.

Further details about MenQuadfi® vaccine can be found in the Summary of Product Characteristics (SmPC).

Contact helpdesk@immform.org.uk for ordering queries.

Change of vaccine for the pertussis (whooping cough) vaccination in pregnancy programme from 1 July 2024

From 1 July 2024, the vaccine used for the pertussis (whooping cough) vaccination in pregnancy programme changed from Boostrix-IPV® to ADACEL®. Please refer to the prenatal pertussis vaccine change letter from July 2024.

ADACEL® is now available to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Boostrix-IPV® continues to be the vaccine used for the pre-school booster vaccination of children, and for the maternal programme if ADACEL® is not available or is otherwise unsuitable (such as in individuals with a severe allergy to latex).

Providers who do not administer pre-school boosters, and were unable to use up locally held stock of Boostrix-IPV® ahead of the change on 1 July 2024, may offer any remaining locally held stock of Boostrix-IPV® to pregnant women if this will prevent vaccine wastage.

ADACEL® vaccine ordered via ImmForm is supplied as a single-dose pack, containing one pre-filled syringe. The pack does not contain a needle for administration. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. Needles should be obtained locally.

Please add ADACEL® to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock.

Details about the pertussis (whooping cough) vaccination programme is published in chapter 24 of the Green Book.

Further details about ADACEL® vaccine can be found in the SmPC.

Contact helpdesk@immform.org.uk for ordering queries.

Introduction of Abrysvo® RSV vaccine for older adults and during pregnancy for infant protection

From 1 September 2024, RSV (respiratory syncytial virus) programmes were introduced for older adults and during pregnancy for infant protection. Please refer to the letter introducing the new NHS programmes against RSV.

The same RSV vaccine, Abrysvo®, is used for both programmes.

Abrysvo® vaccine is now available to order via ImmForm. Customers in Scotland should refer to local ordering guidance. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. Any further updates to ordering information will be published online as an ImmForm news article.

Abrysvo® vaccine ordered via ImmForm is supplied as a single-dose pack, containing one vial of vaccine, diluent for reconstitution and a PIL.

Each pack also contains one 25G x 25mm (1”) needle. Guidance on the choice of needle size can be found in chapter 4 of the Green Book. If required, other sizes of needles should be obtained locally.

The pack of Abrysvo® vaccine is physically larger than most other vaccines supplied via ImmForm. The vaccine must be stored between 2 to 8˚C. Please ensure you have enough fridge capacity before placing any orders. To help with planning storage requirements, each single dose pack measures 73mm x 35mm x 116mm (H x W x D).

When ordering Abrysvo® vaccine, orders should be placed for the ImmForm product that is specific to each RSV protection programme.

Product ordered for the infant RSV protection programme (offered to pregnant women) should not be used for the older adult RSV protection programme and vice versa. Account holders will see two different product lines and should order accordingly.

To minimise wastage due to fridge failures, please order no more than 2 weeks’ worth of stock. 

Details about the RSV vaccination programmes is published in chapter 27a of the Green Book.

Further details about Abrysvo® vaccine can be found in the SmPC.

Contact helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2024 to 2025 children’s flu programme supplied by UKHSA

All flu vaccines for the 2024 to 2025 children’s flu programme are available to order by NHS providers in England via ImmForm.

UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Important update regarding the live attenuated influenza vaccine (LAIV)

From 2024, LAIV will be a trivalent vaccine (rather than a quadrivalent) due to the removal of the B-Yamagata strain. This change in formulation by AstraZeneca was recommended by the World Health Organization and is supported by the JCVI. The brand name for the trivalent vaccine is Fluenz® (the quadrivalent vaccine was named Fluenz® Tetra).

Presentation of the vaccine (that is, pre-filled single-dose nasal spray, supplied in a 10-dose pack) remains the same, and LAIV is available to order via ImmForm for providers of the children’s flu programme as usual.

Vaccines and availability

The 2 vaccines that are available, and the groups that these vaccines should be ordered for, are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	all children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years[footnote 1]
Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc)	Seqirus	children in clinical risk groups aged 6 months to <2 years, and all other eligible[footnote 2] children aged 2 to <18 years for whom LAIV is unsuitable

The latest and most accurate information on availability of centrally supplied vaccines for the children’s flu programme is available on the ImmForm news page at all times. It is strongly advised that all parties involved in the provision of influenza vaccines to children ensure they remain up to date with this.

Editing Fluenz® (LAIV) orders

Due to the anticipated large volume of orders for Fluenz® in the first few weeks of ordering, orders for this product will be assembled as soon as they are placed and will not be editable. If you need to make an adjustment to your order after it has been placed, you will need to contact helpdesk@immform.org.uk for assistance.

LAIV ordering information for General Practice

Ordering controls are in place for general practices, to enable UKHSA to balance supply with demand. These controls work by allocating an amount of LAIV based on the number of registered eligible patients and are tailored to each practice. GPs are able to place one order and receive one delivery of LAIV per week.

At this time:

• each GP practice has been allocated sufficient LAIV to vaccinate at least 45% of their eligible patients (all 2- and 3-year-olds, plus children in clinical risk groups from age 4 to <18 years)
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period. Requests for additional vaccine should be sent to helpdesk@immform.org.uk and should be sent in good time before your order cut-off. Out-of-schedule deliveries will be by exception only

Multi-branch practices and LAIV allocations

Please note that GP practices or groups that operate over multiple sites but are part of the same organisation will have a joint allocation (as in previous years), even where each site has a unique ImmForm account. This means that it is possible for one site to potentially order all of the available vaccine for the group, unless there is local agreement on how the allocated volume is shared. UKHSA recommends that this agreement is in place before ordering commences to reduce the risk of supply interruption. The information above allows practices to estimate the amount of vaccine they will be initially allocated, and how it should be split between all sites.

LAIV ordering information for school-age providers

School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11:55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering days.

Order day (before 11:55am cut-off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders. 

Please note that this 48-hour delivery schedule does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week will be in place for school provider accounts.

Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) (QIVc) is available to order, in a single-dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to <18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls are also in place for this vaccine as follows:

• for GPs, there is a cap of 10 doses/packs per week
• for school-age providers, there is a cap of 450 doses/packs per week

All influenza vaccines for the 2024 to 2025 season

Information on all influenza vaccines that have been marketed in the UK for the 2024 to 2025 season is available here.

The impact of changes to opening hours on routine vaccine deliveries

Please consider temporary changes to opening times when placing ImmForm orders. If you are aware of a scheduled site closure, please refrain from placing an order for that date. In case of a one-off closure, consider rescheduling your order for the week before or after. This approach will contribute to improved overall efficiencies and enhance delivery performance for the benefit of all customers.

It is not possible to accommodate one-off changes to delivery days. Customers should report long-term changes to the days and times when they can accept deliveries, such as routine training days and closures, by contacting Movianto UK Customer Care via email at moviantouk.nhscc@movianto.com or by phoning 01234 587 207. This should not be used to report short-term changes due to absence or holidays.

DTaP/IPV/Hib/HepB vaccine ordering

Supplies of DTaP/IPV/Hib/HepB vaccines Infanrix hexa® and Vaxelis® are available for the routine infant primary immunisations programme.

Orders for Infanrix hexa® remain unrestricted. Customers in England and Wales may order up to 20 packs of Vaxelis® per ImmForm account per week. Customers in Scotland should refer to their local ordering restrictions. Providers should not order more than 2 weeks’ worth of stock to minimise wastage due to fridge failures.  For assistance, please contact helpdesk@immform.org.uk.

The EU Falsified Medicines Directive and Delegated Regulation as applicable to UKHSA-supplied vaccines for the national immunisation programme

The EU Falsified Medicines Directive 2011/62/EU (FMD) and Delegated Regulation ((EU) 2016/161) (the Delegated Regulation) impose legal obligations on the EU medicines supply chain to prevent entry of falsified medicinal products into the supply chain. The Delegated Regulation was implemented in all EU Member States on 9 February 2019. Following the UK’s departure from the EU, the Delegated Regulation ceased to apply in Great Britain from 31 December 2020, but continues to apply in Northern Ireland.

Information for customers in Northern Ireland

FMD-barcoded packs of routine immunisation programme vaccines that are centrally supplied by UKHSA continue to be supplied with active FMD serialisation, and should be decommissioned by end users in Northern Ireland. Customers in Northern Ireland who access centrally supplied vaccines are encouraged to review local guidance on implementation of the FMD.

MMR vaccine ordering

To rebalance central supplies of both MMR vaccines, please consider ordering M-M-RvaxPRO® as your first choice, which is available to all customers without restriction.

Customers in England and Wales who require Priorix®, for example because you serve communities that do not accept vaccines containing porcine gelatine, may order up to 12 packs of Priorix® per ImmForm account per week. For assistance with ordering more than 12 packs of Priorix®, please email your request to helpdesk@immform.org.uk.   

Customers in Scotland should refer to their local ordering restrictions.

Non-routine vaccine supply

Hepatitis A vaccine                   

Adult:

• GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available
• Sanofi: Avaxim PFS singles are currently available. Avaxim packs of 10 are currently available
• MSD: VAQTA Adult is available         

Paediatric:                       

• GSK: supply of Havrix Paediatric singles and packs of 10 are currently available
• MSD: VAQTA Paediatric is available
• Sanofi: Avaxim Junior singles are currently available

Hepatitis B vaccine                             

Adult:                     

• GSK: Engerix B PFS singles and packs of 10 are currently available
• GSK: supply of Fendrix is currently available
• MSD: HBVAXPRO 10µg is available
• MSD: HBVAXPRO 40µg is available
• Valneva: PreHevbri is available

Paediatric:                        

• GSK: supplies of Engerix B Paediatric singles are currently available
• MSD: HBVAXPRO 5µg is available

Combined hepatitis A and B vaccine                      

• GSK: Twinrix Adult singles and packs of 10 are available
• GSK: Twinrix Paediatric is currently available
• GSK: Ambirix is available

Combined hepatitis A and typhoid vaccine                      

Sanofi: Viatim is now a discontinued product and no longer available for sale

Typhoid vaccine             

• Sanofi: Typhim singles and packs of 10 are available
• Patientric: Vivotif is available

Rabies vaccine                         

• Valneva: Rabipur is currently available
• Sanofi: Verorab is available to order with some restrictions (300 doses per month per customer)

Pneumococcal polysaccharide vaccine (PPV)                 

MSD: supply of Pneumovax 23 (PPV23) PFS is available                                   

Pneumococcal polysaccharide conjugate vaccine (PCV)           

• Pfizer: Prevenar 13 is currently available
• MSD: Vaxneuvance is currently available

Varicella zoster vaccine                      

• GSK: VARILRIX is currently available
• MSD: VARIVAX is available.
• MSD: ZOSTAVAX is a discontinued product

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine                           

Sanofi: Revaxis is available                                                 

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

• GSK: supply of Boostrix-IPV is currently available
• Sanofi: Repevax is currently available

MMR                     

• MSD: MMR Vaxpro is currently available
• GSK: Priorix is currently available

Meningitis ACWY vaccine                             

• GSK: Menveo is currently available
• Pfizer: Nimenrix is currently available
• Sanofi: MenQuadfi is available

Yellow fever          

Sanofi: Stamaril is available        

Human papillomavirus vaccine  

• MSD: GARDASIL has been discontinued
• MSD: Gardasil 9 is currently available
• GSK: Cervarix has been discontinued

Cholera vaccine                        

• Valneva: Dukoral is available
• Patientric: Vaxchora is available

Japanese encephalytis vaccine                    

Valneva: Ixiaro is available                    

Meningococcal group B vaccine

GSK: Bexsero is currently available       

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available

Hib and meningococcal group C combined vaccine

GSK: Menitorix is currently available                

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available                   

Herpes zoster vaccine    

GSK: Shingrix is currently available

Diphtheria, tetanus and pertussis

Sanofi: Adacel is available to order without restrictions         

Dengue tetravalent vaccine

Takeda: Qdenga is currently available

1. unless LAIV clinically contraindicated or otherwise unsuitable ↩

2. children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to <18 years ↩